Everything below concerns Mass spectrometry. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2026-02-08. Numbers and descriptions here follow the published literature rather than marketing material.
A persistent misconception is that cardarine is a fat-burning drug or a safe alternative to anabolic steroids. No approved therapeutic product exists, and human safety data are limited. The tumor findings in rodents remain a central concern in scientific reviews. Products sold online may contain inaccurate labels, impurities, or different compounds entirely, which complicates any assessment of effects. Independent testing of such products has reported frequent mislabeling. For these reasons, discussions in the literature emphasize risks and unknowns rather than benefits.
Cardarine is not approved for human therapeutic use in any major jurisdiction. It appears on the World Anti-Doping Agency Prohibited List as a PPARδ agonist within the hormone and metabolic modulators category. Sports organizations test for it because it has been detected in athlete samples and seized products. Regulatory actions against marketed research chemical versions have occurred in several countries, though enforcement varies. Availability through unregulated channels complicates oversight.
Analytical laboratories typically identify cardarine and its metabolites using liquid chromatography-tandem mass spectrometry. Urine is a common matrix in anti-doping testing, while blood and tissue may be used in research settings. Detection windows depend on the assay, the sample matrix, and the compound's metabolism. Because cardarine is extensively metabolized, laboratories often target specific metabolites to improve sensitivity and confirmation. Reference standards are required for reliable quantification. Method validation includes checks for selectivity, linearity, and carryover.
Stability of GW501516 depends on form, temperature, light exposure, and moisture. Solid reference material is typically stored frozen or refrigerated in a desiccator and protected from light. Solutions in organic solvents such as dimethyl sulfoxide are often kept frozen in aliquots to reduce freeze-thaw cycling. Aqueous solubility is low, so aqueous stock solutions can be difficult to prepare without cosolvents. Degradation may appear as changes in chromatographic purity or mass spectral signal. Stability studies are needed to establish shelf life for any specific preparation.
Quality assessment for cardarine samples usually combines identity, purity, and impurity testing. Nuclear magnetic resonance spectroscopy and mass spectrometry can confirm molecular structure, while high-performance liquid chromatography estimates purity. Certificates of analysis from testing laboratories may list these results, but they do not establish safety or legality. In the absence of approved manufacturing, products sold online may contain the wrong compound, variable amounts, or unlisted contaminants. Independent verification is therefore central to analytical work and to interpreting any reported biological activity.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved for human therapeutic use | No marketing authorization identified in major jurisdictions. |
| Anti-doping class | PPARδ agonist; hormone and metabolic modulators | Listed on the WADA Prohibited List. |
| Common test matrix | Urine | Also blood and tissue in research settings. |
| Typical analytical method | LC-MS/MS | Targets parent compound and metabolites. |
| Major safety signal | Tumor findings in rodents | Human relevance not established; limited human data. |
Cardarine is a common name for GW501516, an investigational compound developed in the 1990s for metabolic conditions. It acts as an agonist at peroxisome proliferator-activated receptor delta, a nuclear receptor involved in lipid and energy metabolism. The compound is frequently mislabeled as a selective androgen receptor modulator, or SARM, but its molecular target is different. GW501516 reached early clinical testing before development was discontinued. It has no approved therapeutic use in any country. The name cardarine is not a formal international nonproprietary name.
Regulatory treatment varies, but cardarine is not approved as a medicine. Sports authorities list GW501516 as a prohibited substance, and it is banned at all times under the World Anti-Doping Agency code. Many countries restrict sales for human consumption, while online vendors market it as a research chemical. Such products may lack purity data, and their actual contents can differ from the label. Purchasing or possessing cardarine may carry legal consequences depending on jurisdiction. The compound is not a dietary supplement ingredient in regulated markets.
Regulatory treatment of cardarine differs by context and jurisdiction. In competitive sport, the World Anti-Doping Agency lists PPARδ agonists, including GW501516, as prohibited at all times. Outside sport, it lacks approval as a prescription medicine in major drug markets, and products sold for human consumption may be treated as unapproved drugs. Some countries also restrict importation or sale through general consumer protection and medicines laws. These classifications affect availability, testing, and legal risk without establishing therapeutic value.
Because cardarine is not an approved medicine, no pharmacopeial monograph defines its identity, purity, or storage requirements. Laboratories typically rely on in-house methods and reference standards when testing materials labeled as GW501516. Certificates of analysis may report purity and identity for a specific batch, but their scope varies and they do not guarantee safety or legal status. Independent verification can include high-performance liquid chromatography, mass spectrometry, nuclear magnetic resonance, and elemental analysis. The distinction between research chemical labeling and human use is significant because quality standards and oversight differ.
Cardarine can be detected in biological samples and product materials using liquid chromatography coupled to tandem mass spectrometry (LC-MS/MS). The method separates compounds by chromatography and identifies them by mass-to-charge transitions, allowing low-level detection in urine or blood. Sample preparation often involves enzymatic hydrolysis, solid-phase extraction, or protein precipitation. Certified reference materials and isotope-labeled internal standards improve quantification. Detection windows depend on metabolism, matrix, and assay sensitivity, so no single universal window applies.
3-Glucuronidation to oxymorphone-3-glucuronide predominantly via UGT2B7 6-Ketoreduction to 6α-oxymorphol and 6β-oxymorphol N-Demethylation to noroxymorphone The first pathway of the above three accounts for 40% of the metabolism of oxymorphone, making oxymorphone-3-glucuronide the main metabolite of oxymorphone, while the latter two pathways account for less than 10% of the metabolism of oxymorphone. After N-demethylation of oxymorphone, noroxymorphone is further glucuronidated to noroxymorphone-3-glucuronide. Because oxycodone is metabolized by the cytochrome P450 system in the liver, its pharmacokinetics can be influenced by genetic polymorphisms and drug interactions concerning this system, as well as by liver function. Some people are fast metabolizers of oxycodone, while others are slow metabolizers, resulting in polymorphism-dependent alterations in relative analgesia and toxicity. While higher CYP2D6 activity increases the effects of oxycodone (owing to increased conversion into oxymorphone), higher CYP3A4 activity has the opposite effect and decreases the effects of oxycodone (owing to increased metabolism into noroxycodone and noroxymorphone). The dose of oxycodone must be reduced in patients with reduced liver function.
== Gene == The RAGE gene lies within the major histocompatibility complex (MHC class III region) on chromosome 6 and comprises 11 exons interlaced by 10 introns. Total length of the gene is about 1400 base pairs (bp) including the promoter region, which partly overlaps with the PBX2 gene. About 30 polymorphisms are known most of which are single-nucleotide polymorphisms.
Certain regions of an organism's genome will be more or less likely to undergo mutation depending on the presence of DNA repair mechanisms and other mutation biases. For instance, in a study on Arabidopsis thaliana, biologically important regions of the plant's genome were found to be protected from mutations, and beneficial mutations were found to be more likely, i.e. mutation was "biased in a way that benefits the plant". Mammals did not evolve from any modern group of reptiles; rather, mammals descend from a Reptiliomorph, or reptile-like, ancestor. After the first fully terrestrial tetrapods evolved, one of their lineages split into the synapsids (the line leading to mammals) and the diapsids (the line leading to reptiles, including birds). The synapsids and the diapsids diverged about 320 million years ago, in the mid-Carboniferous period. The mammals themselves are the only survivors of the synapsid line. Humans and other apes are Old World monkeys. There is a concerted social and religious effort to deny evidence which connects humans to their ancestors and fellow extant simians, but there is no way to naturally define the monkeys while excluding humans and other apes. Humans did not evolve from either of the living species of chimpanzees or any other living species of apes. Humans and chimpanzees did, however, evolve from a common ancestor. This most recent common ancestor of living humans and chimpanzees would have lived between 5 and 8 million years ago.
Svarthöna, Bohuslän-Dals svarthöna, or Swedish Black Chicken is a Swedish landrace of domestic chickens that is considered to have originated from Ayam Cemani/Kadaknath breeds of chickens transported from Mozambique to Norway by sailors sometime in the 17th century. The Svarthöna has since adapted to a northerly climate, it but has retained the rare quality of black skin and connective tissue. The current form of Svarthöna has been given the status of a landrace. All Swedish entries in gene banks can be traced to a group of chickens that came to Sweden around the turn of the 19th century. In 1956, this flock was bought by two brothers in Bullarebygd. The Swedish Association for Landrace Breeds has preserved the Svarthöna in a gene bank since 1991. A rooster can weigh up to 2 kg, whilst hens do not exceed 1.5 kg. The eggs are small (38-48 g) with a large yolk. The Svarthöna has some flight ability. The black pigmentation found in skin and connective tissue has been shown to be caused by a variant of the gene EDN3, a trait shared with the Chinese Silkie, Indonesian Ayam Cemani, and Vietnamese Black H'Mong.
Sources: en.wikipedia.org
The Parliament of Barbados is the legislative branch of the government of Barbados. It is a bicameral body, composed of an appointed Senate and an elected House of Assembly. The Senate (upper house), the direct successor of a pre-Independence body known as the "Legislative Council"—comprises 21 senators appointed by the president. The President appoints 12 Senators on the advice of the Prime Minister and two on the advice of the Leader of the Opposition. The remaining seven Senators are nominated by the President at their discretion (that is, the President is not bound by other political leaders' advice in these appointments) to represent various religious, social, economic, or other interests in Barbados. In the absence of an opposition leader in parliament (i.e. in the case of a landslide victory where one party takes all 30 seats in the House of Assembly, as occurred in 2018 and 2022) the president will then appoint the remaining two senators in the opposition's stead allowing for 9 independents instead. The House of Assembly (lower house) is made up of 30 members of Parliament, elected to five-year terms on a first-past-the-post basis in single-seat constituencies.
=== Microfaunal interactions === The apothecia of Xanthoria parietina also host microscopic animals. Members of the rotifer genus Philodina have been observed feeding on the lichen's ascospores present on apothecial surfaces. Individual rotifers can accumulate several dozen spores, and when ingesting 20 or more spores, about 15% remain viable and capable of germination after excretion. These findings indicate that rotifers may act as dispersal vectors, dislodging and releasing viable spores in new locations.
=== Companies === To translate his discoveries into therapeutics, Verdine has founded or co-founded numerous public biotech companies including Variagenics, Enanta, Eleven Bio, Tokai, Wave Life Sciences, and Aileron. He also founded the private company Gloucester Pharmaceuticals, which was acquired by Celgene in 2009. His companies share the mission of developing molecules intended to target “hard-to-drug” endogenous targets that have remained out of reach of modern cell-penetration technologies.
Sources: en.wikipedia.org
South Africa In South Africa, the five-door-only 323 proved an immediate success. The 1.3 was gradually replaced by the larger 1.4 from July 1978, while a Special and a CS model were added at the low and high ends of the lineup respectively, complementing the existing De Luxe models. Well-equipped versions of the 1978 facelift model were sold as the "323 GLC" in South Africa. A 1600-cc model was also available in South Africa – however this model did not have a Mazda engine, unlike the rest of the range. To satisfy that country's local content regulations, a locally built Mitsubishi Saturn 1.6-litre unit was used. This produces 77 PS (57 kW) and was the most powerful engine to be installed in the FA-series Familia/323. It arrived in early 1979, but period testers felt that the less-revvy 1.6 provided very little that the 1.4 did not offer, and could not be considered to be worth the price. Fuel consumption dropped, while top speed of 148 km/h (92 mph) was only marginally higher than the 145 km/h (90 mph) of the smaller version. Sigma also fielded a rotary-engined 323 in the South African national rally championship.
== Y == Ada Yonath (1939–2026). Israeli crystallographer at the Weizmann Institute of Science, best known for her pioneering work on the structure of the ribosome. Nobel Prize in Chemistry (2009). Member Natl. Acad. Sci. USA. Frank Young FRS (1908–1988). British biochemist at Cambridge University, where he was Sir William Dunn Professor for many years. William John Young (1878–1942). British biochemist at the University of Melbourne who worked on fermenting enzymes in yeast extract, and discovered “Harden–Young ester” (fructose 1,6-bisphosphate).
== NeuCode SILAC == Traditionally the level of multiplexing in SILAC was limited due to the number of SILAC isotopes available. Recently, a new technique called NeuCode (neutron encoding) SILAC, has augmented the level of multiplexing achievable with metabolic labeling (up to 4). The NeuCode amino acid method is similar to SILAC but differs in that the labeling only utilizes heavy amino acids. The use of only heavy amino acids eliminates the need for 100% incorporation of amino acids needed for SILAC. The increased multiplexing capability of NeuCode amino acids is from the use of mass defects from extra neutrons in the stable isotopes. These small mass differences however need to be resolved on high-resolution mass spectrometers.
=== Sources === Philippe Jaussaud; Édouard-Raoul Brygoo (2004). Du Jardin au Muséum. Archives (in French). Paris: Muséum national d'histoire naturelle. p. 630. ISBN 978-2-85653-565-3. Annuaire et sites du Muséum national d'histoire naturelle, 40 p., MNHN, Paris, rééditions décennales. Ghislaine Prévos, Service documentation du Département des Galeries du Muséum national d'histoire naturelle, annuaire biographique du personnel.
Sources: en.wikipedia.org
No. Cardarine has not received approval for human therapeutic use in major jurisdictions. It remains an investigational compound.
It is classified as a PPARδ agonist on the WADA Prohibited List. Anti-doping laboratories can detect it and its metabolites in urine. Its use is banned in competition and usually out of competition.
Rodent studies reported increased tumor incidence at multiple sites. The human relevance remains uncertain, but the findings contributed to discontinuation of development. No long-term human cancer data are available.
LC-MS/MS is common, often after sample cleanup. The assay targets GW501516 or its metabolites.